Cambium Bio (ASX:CMB) EPS (Basic): A$-0.19 (TTM As of Dec. 2025)


ASX:CMB Cambium Bio Ltd ASX:CMB
35 GF Score
Price A$0.42
! 4 Warning Signs
View Full Analysis

What is Cambium Bio EPS (Basic)?

Cambium Bio ASX:CMB -6.74% 35 EPS (Basic) is A$-0.19 as of Dec. 2025. GuruFocus rates ASX:CMB with a GF Score™ of 35/100. The stock has 4 warning signs investors should review.

Cambium Bio's basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was A$-0.07. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.19.

Cambium Bio's EPS (Diluted) for the six months ended in Dec. 2025 was A$-0.07. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.19.

Cambium Bio's EPS without NRI for the six months ended in Dec. 2025 was A$-0.07. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -0.19.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Cambium Bio  (ASX:CMB) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Cambium Bio EPS (Basic) Related Terms

Cambium Bio EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Cambium Bio's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cambium Bio EPS (Basic) Chart

Cambium Bio Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.70 -1.40 -1.10 -0.54 -0.21

Cambium Bio Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.40 -0.10 -0.14 -0.12 -0.07
ASX:CMB
35GF Score
Cambium Bio Ltd ASX:CMB
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cambium Bio EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Cambium Bio's Basic EPS for the fiscal year that ended in Jun. 2025 is calculated as

Basic EPS (A: Jun. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-3.844-0)/18.283
=-0.21

Cambium Bio's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-1.456-0)/21.499
=-0.07

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of A$-0.19 mean?
Cambium Bio (ASX:CMB) has a EPS (Basic) of A$-0.19 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Cambium Bio and its competitors.
Is Cambium Bio's EPS (Basic) too high?
Cambium Bio's current EPS (Basic) is A$-0.19. Overall, Cambium Bio has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Cambium Bio's EPS (Basic) compare to VRTX and REGN?
Cambium Bio's EPS (Basic) of A$-0.19 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Cambium Bio and its competitors. Cambium Bio's current EPS (Basic) is A$-0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambium Bio stock overvalued right now?
Cambium Bio (ASX:CMB) has a current EPS (Basic) of A$-0.19. The current EPS (Basic) is A$-0.19. Cambium Bio's overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Cambium Bio (ASX:CMB), the current EPS (Basic) is A$-0.19 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cambium Bio Business Description

Address Unit 2.06, 31 Lexington Drive, Bella Vista, NSW, AUS, 2153
Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate, Elate Ocular, is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.
35GF Score

Get the complete analysis for ASX:CMB

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.42
Price